Table 1.
Magnitudes of BCMA ALS responses can be used to identify strong and weak IgA vaccine responders.
| Magnitude of ALS BCMA response following primary vaccination | Primary vaccination (n = 25) | Booster vaccination (n = 25) | ||
|---|---|---|---|---|
| Non-IgA respondersa | Strong IgA respondersb | Non-IgA respondersa | Strong IgA respondersb | |
| (n = 9) | (n = 16) | (n = 8) | (n = 17) | |
| <1.3 | 8 | 0 | 7 | 1 |
| >1.4 | 1 | 16 | 1 | 16 |
| P-valuec | P < 0.0001 | P < 0.001 | ||
a
ALS IgA combined response index to all five ETVAX vaccine antigens <135.
b
ALS IgA combined response index to all five ETVAX vaccine antigens >150.
c
Assessed by Fishers exact test.
Fisher's exact test was performed to examine the relationship between ALS BCMA magnitudes >1.4 and <1.3 following primary ETVAX vaccination and the ALS IgA combined response index's >150 and <135 following primary or booster ETVAX vaccination.